Literature DB >> 25695748

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.

Amita Datta-Mannan1, Arunkumar Thangaraju, Donmienne Leung, Ying Tang, Derrick R Witcher, Jirong Lu, Victor J Wroblewski.   

Abstract

Lowering the isoelectric point (pI) through engineering the variable region or framework of an IgG can improve its exposure and half-life via a reduction in clearance mediated through non-specific interactions. As such, net charge is a potentially important property to consider in developing therapeutic IgG molecules having favorable pharmaceutical characteristics. Frequently, it may not be possible to shift the pI of monoclonal antibodies (mAbs) dramatically without the introduction of other liabilities such as increased off-target interactions or reduced on-target binding properties. In this report, we explored the influence of more subtle modifications of molecular charge on the in vivo properties of an IgG1 and IgG4 monoclonal antibody. Molecular surface modeling was used to direct residue substitutions in the complementarity-determining regions (CDRs) to disrupt positive charge patch regions, resulting in a reduction in net positive charge without affecting the overall pI of the mAbs. The effect of balancing the net positive charge on non-specific binding was more significant for the IgG4 versus the IgG1 molecule that we examined. This differential effect was connected to the degree of influence on cellular degradation in vitro and in vivo clearance, distribution and metabolism in mice. In the more extreme case of the IgG4, balancing the charge yielded an ∼7-fold improvement in peripheral exposure, as well as significantly reduced tissue catabolism and subsequent excretion of proteolyzed products in urine. Balancing charge on the IgG1 molecule had a more subtle influence on non-specific binding and yielded only a modest alteration in clearance, distribution and elimination. These results suggest that balancing CDR charge without affecting the pI can lead to improved mAb pharmacokinetics, the magnitude of which is likely dependent on the relative influence of charge imbalance and other factors affecting the molecule's disposition.

Entities:  

Keywords:  125I, Iodine 125; AUC, area under the curve; CDR modification; CDR, complementarity-determining region; ELISA, enzyme-linked immunosorbent assay; FcRn recycling; FcRn, neonatal Fc receptor; HBSS, Hank's balanced salt saline solution; HEK293 cells; IV, intravenous; IgGs, immunoglobulins; KD, equilibrium dissociation constant; KDa, kilodalton; PK, pharmacokinetics; SD, standard deviation; SPR, surface plasmon resonance; TCA, trichloroacetic acid; TMDD, target-mediated drug disposition; antibody pharmacokinetics; charge interactions of IgGs; in vitro degradation; non-specific binding; pI, isoelectric point; radiolabel antibody biodistribution

Mesh:

Substances:

Year:  2015        PMID: 25695748      PMCID: PMC4622971          DOI: 10.1080/19420862.2015.1016696

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  25 in total

Review 1.  Therapeutic antibodies: market considerations, disease targets and bioprocessing.

Authors:  John G Elvin; Ruairidh G Couston; Christopher F van der Walle
Journal:  Int J Pharm       Date:  2011-12-30       Impact factor: 5.875

2.  Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes.

Authors:  Yin Guo; Robert A Jolly; Bartley W Halstead; Thomas K Baker; John P Stutz; Melanie Huffman; John N Calley; Adam West; Hong Gao; George H Searfoss; Shuyu Li; Armando R Irizarry; Hui-Rong Qian; James L Stevens; Timothy P Ryan
Journal:  Toxicol Sci       Date:  2007-01-25       Impact factor: 4.849

3.  An engineered human IgG1 antibody with longer serum half-life.

Authors:  Paul R Hinton; Joanna M Xiong; Mary G Johlfs; Meina Tao Tang; Stephen Keller; Naoya Tsurushita
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

4.  Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.

Authors:  Amita Datta-Mannan; Derrick R Witcher; Ying Tang; Jeffry Watkins; Weidong Jiang; Victor J Wroblewski
Journal:  Drug Metab Dispos       Date:  2006-10-18       Impact factor: 3.922

5.  Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.

Authors:  Amita Datta-Mannan; Derrick R Witcher; Ying Tang; Jeffry Watkins; Victor J Wroblewski
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

Review 6.  The sweet and sour of cancer: glycans as novel therapeutic targets.

Authors:  Mark M Fuster; Jeffrey D Esko
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

7.  Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization.

Authors:  W M Pardridge; Y S Kang; J Yang; J L Buciak
Journal:  J Pharm Sci       Date:  1995-08       Impact factor: 3.534

8.  Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Authors:  Herren Wu; David S Pfarr; Syd Johnson; Yambasu A Brewah; Robert M Woods; Nita K Patel; Wendy I White; James F Young; Peter A Kiener
Journal:  J Mol Biol       Date:  2007-02-20       Impact factor: 5.469

Review 9.  Elimination mechanisms of therapeutic monoclonal antibodies.

Authors:  Mohammad A Tabrizi; Chih-Ming L Tseng; Lorin K Roskos
Journal:  Drug Discov Today       Date:  2006-01       Impact factor: 7.851

10.  Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor.

Authors:  Devin B Tesar; Noreen E Tiangco; Pamela J Bjorkman
Journal:  Traffic       Date:  2006-09       Impact factor: 6.215

View more
  49 in total

1.  Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.

Authors:  Patrick M Glassman; Yang Chen; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-12       Impact factor: 2.745

2.  Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries.

Authors:  Ryan L Kelly; Doris Le; Jessie Zhao; K Dane Wittrup
Journal:  J Mol Biol       Date:  2017-11-26       Impact factor: 5.469

Review 3.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

4.  High-throughput retrieval of physical DNA for NGS-identifiable clones in phage display library.

Authors:  Jinsung Noh; Okju Kim; Yushin Jung; Haejun Han; Jung-Eun Kim; Soohyun Kim; Sanghyub Lee; Jaeseong Park; Rae Hyuck Jung; Sang Il Kim; Jaejun Park; Jerome Han; Hyunho Lee; Duck Kyun Yoo; Amos C Lee; Euijin Kwon; Taehoon Ryu; Junho Chung; Sunghoon Kwon
Journal:  MAbs       Date:  2019-02-12       Impact factor: 5.857

Review 5.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

Review 6.  Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.

Authors:  Miroslav Dostalek; Thomayant Prueksaritanont; Robert F Kelley
Journal:  MAbs       Date:  2017-05-02       Impact factor: 5.857

7.  Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.

Authors:  Deni Hardiansyah; Chee Meng Ng
Journal:  MAbs       Date:  2018-07-30       Impact factor: 5.857

8.  Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.

Authors:  Claudia A Castro Jaramillo; Sara Belli; Anne-Christine Cascais; Sherri Dudal; Martin R Edelmann; Markus Haak; Marie-Elise Brun; Michael B Otteneder; Mohammed Ullah; Christoph Funk; Franz Schuler; Silke Simon
Journal:  MAbs       Date:  2017-04-25       Impact factor: 5.857

9.  Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.

Authors:  Amita Datta-Mannan; Johnny E Croy; Linda Schirtzinger; Stacy Torgerson; Matthew Breyer; Victor J Wroblewski
Journal:  MAbs       Date:  2016-07       Impact factor: 5.857

Review 10.  Targeting FcRn to Generate Antibody-Based Therapeutics.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Trends Pharmacol Sci       Date:  2018-08-22       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.